

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	Weiner <i>et al.</i>	Confirmation No.:	8108
Patent No.	7,601,740	Issued:	October 13, 2009
Serial No.:	10/759,561	Art Unit:	1617
Filed:	January 15, 2004	Examiner:	Jennifer M. Kim
For:	SELECTIVE SEROTONIN 2A/2C RECEPTOR INVERSE AGONISTS AS THERAPEUTICS FOR NEURODEGENERATIVE DISEASES	Attorney Docket No:	12560-016-999
		CAM:	598154-999016

REQUEST FOR CERTIFICATE OF CORRECTION UNDER 37 C.F.R. § 1.323

Office of Patent Publication
Attn: Certificate of Correction Branch
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

Pursuant to 37 C.F.R. § 1.323, Patentee hereby respectfully requests the issuance of a Certificate of Correction in connection with the above-identified patent. The correction of errors in the patent are described below and on the attached Form PTO/SB/44. Each error is of a clerical or typographical error. More specifically, the requested changes are to correct misspelled chemical names and to add missing open parentheses. Correction of the errors does not constitute new matter or require reexamination of the patent. *See* 35 U.S.C. § 255; *In re Arnott*, 19 U.S.P.Q.2d 1049, 1052 (Comm'r Pat. 1991).

At column 3, please replace the text “ephedrine” at line 43 with --ephedrine--; the text “CYLERTTM” at line 44 with --(CYLERTTM)--; the text “methylphenydate” at line 45 with --methylphenidate--; the text “haloperodol” at lines 59-60 with --haloperidol--; the text “butyrophenome” at line 61 with --butyrophenone--; the text “diphenulbutylpiperinde” at line 62 with --diphenylbutylpiperidine--; and the text “fluphenthixol” at line 63 with --flupenthixol--.

At column 4, please replace the text “ephedrine” at line 22 with --ephedrine--; the text “CYLERTTM” at line 23 with --(CYLERTTM)--; and the text “methylphenydate” line 25 with --methylphenidate--.

At column 5, please replace the text “haloperodol” at line 18 with --haloperidol--; the text “butyrophenome” at line 20 with --butyrophenone--; the text “diphenulbutylpiperinde” at lines 20-21 with --diphenylbutylpiperidine--; the text “fluphenthixol” at line 21 with --flupenthixol--; the text “9-OH-risperdone” at line 25 with --9-OH-risperidone--; the text “haloperodol” at line 45 with --haloperidol--; the text “butyrophenome” at line 47 with --butyrophenone--; the text “diphenulbutylpiperinde” at lines 47-48 with --diphenylbutylpiperidine--; and the text “9-OH-risperdone” at line 52 with --9-OH-risperidone--.

At column 19, please replace the text “ephenedrine” at line 18 with --ephedrine--; the text “CYLERT™” at line 19 with --(CYLERT™)--; the text “methylphenydate” at line 21 with --methylphenidate--; the text “haloperodol” at line 33 with --haloperidol--; the text “butyrophenome” at line 35 with --butyrophenone--; the text “diphenulbutylpiperinde” at line 35 with --diphenylbutylpiperidine--; the text “fluphenthixol” at line 36 with --flupenthixol--; and the text “9-OH-risperdone” at line 40 with --9-OH-risperidone--.


In claim 3, please replace the text “ephenedrine” at line 56 with --ephedrine--.

In claim 8, please replace the text “haloperodol” at line 8 with --haloperidol--; the text “thiordazine” at line 9 with -- thioridazine --; the text “fluphenthixol” at line 11 with --flupenthixol--; and the text “9-OH-risperdone” at line 14 with --9-OH-risperidone--.

Please issue a Certificate of Correction in due course. The fee of \$100.00 for the Certificate of Correction under 37 C.F.R § 1.20(a) will be paid concurrently herewith via EFS WEB. The Commissioner is authorized to charge any other required fee or credit any overpayments to Jones Day Deposit Account No. 50-3013 (order no. 598154-999016).

Respectfully submitted,

Date: November 24, 2009


by: Mark D. Kafka
for: Anthony M. Insogna

Reg. No. 59,569
Reg. No. 35,203

JONES DAY
222 East 41st Street
New York, New York 10017
(212) 326-3939